GSK Wins Japanese Approval For Cervarix As First Cervical Cancer Vaccine In Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - GlaxoSmithKline K.K., the fully-owned Japanese subsidiary of GlaxoSmithKline, has won Japan's Ministry of Health, Labor and Welfare approval for cervical cancer vaccine Cervarix, the first cervical cancer vaccine to be marketed in Japan, the company announced Oct. 16
You may also be interested in...
GSK Names Former Sanofi Executive As President Of Japanese Affiliate
GlaxoSmithKline has appointed Philippe Fauchet, formerly a senior vice president at Sanofi-Aventis, as the new president of GSK's Japanese subsidiary
GSK Names Former Sanofi Executive As President Of Japanese Affiliate
GlaxoSmithKline has appointed Philippe Fauchet, formerly a senior vice president at Sanofi-Aventis, as the new president of GSK's Japanese subsidiary
GSK Files Japan's First Rotavirus Vaccine; Will Japan Become Next Battleground For Vaccine Makers?
GlaxoSmithKline announced Nov. 30 it is applying for approval for its rotavirus vaccine Rotarix with Japan's Ministry of Health, Labor and Welfare. If approved, it will become the first vaccine in Japan to prevent rotavirus gastroenteritis, a leading cause of diarrhea-related deaths in children